Loading…

Biohaven Ltd.BHVNCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Neuroscience biotech (post-Pfizer Nurtec sale) now developing drugs for ataxia, epilepsy, obesity and neuromuscular disease.

Momentum leader 86
Mkt cap
$1.95B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$56.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 18.1%
Hurdle
n/a
no reverse DCF
Next earnings
110 days
8 Mar 2027
Close · USD$12.90
1D-2.6%
1W-15.1%
1M+9.2%
3M-4.4%
6M+45.8%
YTD+14.3%
1Y+56.0%
ATR %7.5%
Beta1.22
52w lowhigh29.3% off high

What Biohaven does

Neuroscience biotech (post-Pfizer Nurtec sale) now developing drugs for ataxia, epilepsy, obesity and neuromuscular disease.

Became a separate company in 2022 when Pfizer bought the old Biohaven for its migraine drug Nurtec, leaving this new company with the rest of the pipeline. It has no product revenue and is funded by raising money from investors.

Products and services

  • Troriluzole (spinocerebellar ataxia)
  • Taldefgrobep alfa (spinal muscular atrophy/obesity)
  • BHV-7000 (Kv7 opener, epilepsy)

Where it sits in the supply chain

  • Biopharma R&D
  • Neuro/immunology drug development
  • Post-Nurtec pipeline diversification

What could go right

  • Multiple pipeline shots-on-goal readouts
  • Milestone payments from Pfizer Nurtec deal

What could go wrong

  • No approved products generating revenue
  • Multiple binary trial risks

Moat: none (IP / patents). Pre-commercial pipeline company after divesting its only approved drug (Nurtec) to Pfizer.

Headquarters: New Haven, Connecticut, US · Founded: 2013 · Employees: 274

Named competitors

Biohaven at a glance

Size Biohaven (BHVN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.95B, the 1789th largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.90 on 18 Nov 2026.

Performance Over six months the shares gained 45.8%, against -5.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Short interest Short interest is 9.9% of the free float (30 Oct 2026).

Next results Next results expected around 8 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026BHVN 136Peer median 93
Six months, rebased to 100: Biohaven against the median of its 20 peers (local-currency closes).

Biohaven financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$2.86M-$4.14M-$3.92M-$3.37M-$1.39M
EBITDA-$522M-$741M-$881M-$433M-$567M
Net income-$543M-$739M-$846M-$408M-$570M
Free cash flow-$473M-$610M-$587M-$335M-$304M
Capital expenditure$642,000$715,000$4.05M$3.05M$41.1M
Total debt$300M$285M$36.6M$30.9M$68.8M

Quarterly statements and history in the cockpit →

Biohaven competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%+20%ONESOURCEHRMY60020145400512SHILPAMEDERISALIVUS9969009420PFIZER300009300436600211603456603707COHANCE600285000908DMPBHVN6-month return →1-month return →
Up and to the right = strong over both horizons. Biohaven is the large dot.

Biohaven competitors and peer comparison

Head to head with its named competitors (BHVN vs LLY vs NBIX vs XENE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Biohaven BHVN$1.95B+46%n/an/an/an/a
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Neurocrine Biosciences NBIX$16.5B+5%+38%25%4.4×-1.5%
Xenon Pharmaceuticals XENE$3.71B-31%-100%n/an/an/a
Pfizer PFE$160B+9%+1%26%3.3×-4.3%

How Biohaven compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Biohaven against its 20 peers (data as of 18 Nov 2026)
MeasureBHVNPeer medianRank in peer set
1-month return+9.2%+0.3%6th highest of 21
6-month return+45.8%-5.5%2nd highest of 21
Distance from 52-week high-29.3%-28.2%10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%11.8×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%1.4×-10.5%+40.3%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%7.3×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%2.0×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%1.5×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%10.1×n/an/a
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%6.2×26.3%+20.9%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%6.3×20.1%+6.2%
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%2.8×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%16.6×n/an/a
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%5.5×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%4.8×8.0%+9.3%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%30.9×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%3.4×-1.2%+16.7%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%2.4×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%3.2×5.1%+6.4%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%8.6×n/an/a
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%3.3×-4.7%+10.6%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%25.8×n/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%2.3×-3.4%+8.0%

Questions

Who are Biohaven's main competitors?
Named competitors: Eli Lilly (LLY), Neurocrine Biosciences (NBIX), Xenon Pharmaceuticals (XENE), Pfizer (PFE). The cockpit's measured peer set (industry) also includes OneSource Specialty Pharma (ONESOURCE.NS), Harmony Biosciences (HRMY), Jinyu Bio-Technology (600201.SS), Tsumura & (4540.T), Grand Pharmaceutical (0512.HK), Shilpa Medicare (SHILPAMED.NS).
How has Biohaven stock performed?
Over six months to 18 Nov 2026 the shares returned +45.8% against -5.5% for the median peer; over one year +56.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.